A Phase 2 interventional study of WU-CART-007 in T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma, sponsored by Allotera Therapeutics. Recruiting at 18 sites in 2 countries. Open to participants aged 6 Months and older. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by Allotera Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 285 studies in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma with a site in United States — 25 open to participants now, 38 under way, 3 of them phase 3. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma · United States.
Among the 285 studies in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma with a site in United States, this one is the 21st largest by planned enrollment of the 230 interventional ones that give a count, is one of 3 that started in 2025, is one of 80 in phase 2, reaches primary completion later than 14 of the 36 other live ones, and was the 275th registered.
420 studies on the registry are indexed under Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; 76 are open to participants now.
Browse Precursor T-Cell Lymphoblastic Leukemia-Lymphoma studies →25 of the 285 studies in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
M.D. Anderson Cancer Center · Sites in United States
Ages 12–30
Washington University School of Medicine · Sites in United States
Ages up to 30
Baylor College of Medicine · Sites in United States
Ages up to 75
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 60 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 24 (40%) set no upper age limit and 31 (52%) stop at 75 or younger; 36 take children under 18; 1 takes healthy volunteers.
This study: 6 Months and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
285 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 156 · Phase 2 106 · Phase 3 18 · Phase 4 1
First in 1988; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 125 is above the median of 30 across 322 interventional studies indexed under Precursor T-Cell Lymphoblastic Leukemia-Lymphoma.
Median enrollment 30 across the 230 interventional studies, 57 across the 14 observational. Of the 235 that completed or were terminated, 75 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 285 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Allotera Therapeutics as lead sponsor.
Allotera Therapeutics has 1 study filed under Precursor T-Cell Lymphoblastic Leukemia-Lymphoma — fewer than ten, so there is no comparison to draw.
8 of the studies in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05996185Yale UniversityStudy of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma | 2026-11 |
| NCT06514794Allotera TherapeuticsA Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex) | 2026-12-30 |
| NCT04128501M.D. Anderson Cancer CenterVenetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting | 2026-12-31 |
| NCT07388563National Cancer Institute (NCI)Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma | 2027-03-31 |
| NCT04301076National Cancer Institute (NCI)Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL) | 2027-06-30 |
Add all 8 to your calendar (.ics) → With an account.
Among the 285 studies in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The T-RRex study evaluates the efficacy of WU-CART-007 for patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL) and to WU-CART-007 as a therapy to induce complete Minimum Residual Disease (MRD) negative response
This is a Phase 2, single-arm, multi-center, open label study in patients with R/R T-ALL/LBL and T-ALL/LBL in remission but remaining MRD positive.
The criteria were revised on the registry on Sep 28, 2026. See what changed
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A CD7-directed chimeric antigen receptor (CAR) T-cell product. Lymphodepletion
Biological: WU-CART-007
A single IV infusion of WU-CART-007
R/R Cohort - Composite Complete Response Rate
CRc is defined as proportion of patients that achieve a complete remission (CR) + CR with incomplete hematologic recovery (CRi)
Time frame: 24 months
MRD Pos Cohort - Response Rate
Defined as the efficacy of WU-CART-007 to induce complete MRD negative response
Time frame: 24 months
Started Jan 2025 (actual). Primary completion is estimated for Dec 2026, 22 months after the start.
Of 44 phase 2 interventional studies under Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 63 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 97. This study's planned 22 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Allogeneic Anti-CD7 CAR-T Cells WU-CART-007
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma →